What is the recommended dosing of Quilipta (lasmiditan) for migraine prevention?

Quilipta Dosing for Migraine Prevention

For episodic migraine prevention, start with Quilipta (atogepant) 10 mg, 30 mg, or 60 mg once daily taken orally with or without food; for chronic migraine prevention, use 60 mg once daily. 1

Dosing by Migraine Type

Episodic Migraine

The FDA-approved dosing offers three options 1:

• 10 mg once daily
• 30 mg once daily
• 60 mg once daily

All three doses are acceptable first-line choices. Selection should consider cost, tolerability expectations, and individual patient factors.

Chronic Migraine

• 60 mg once daily is the recommended dose 1

Critical Dosing Modifications

Severe Renal Impairment (CrCl <30 mL/min)

• Episodic migraine: Reduce to 10 mg once daily
• Chronic migraine: Avoid use entirely 1

Drug Interactions Requiring Dose Adjustment

Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin):

• Episodic migraine: Reduce to 10 mg once daily
• Chronic migraine: Avoid use 1

CYP3A4 Inducers (strong, moderate, or weak):

• Episodic migraine: Use 30 mg or 60 mg only
• Chronic migraine: Avoid use 1

OATP Inhibitors (e.g., rifampin, cyclosporine):

• Episodic migraine: Limit to 10 mg or 30 mg once daily
• Chronic migraine: Reduce to 30 mg once daily 1

Clinical Context and Positioning

When to Consider Quilipta

According to the 2025 American College of Physicians guidelines, preventive therapy should be considered when 2:

• Severe debilitating headaches persist despite adequate acute treatment
• Patients cannot tolerate or have contraindications to acute treatments
• Acute medications are being used more frequently than recommended

Quilipta (a CGRP antagonist-gepant) is not specifically mentioned in the most recent ACP prevention guidelines 2, which prioritize older, less costly agents. However, it represents a newer therapeutic option in the gepant class.

Cost Considerations

The ACP guidelines emphasize cost as a key factor, noting that annualized wholesale acquisition costs for oral CGRP antagonist-gepants range from $4,959 to $5,994 3. This positions Quilipta as a higher-cost option compared to traditional preventive agents like propranolol, amitriptyline, or topiramate.

Important Safety Considerations

Hypersensitivity Risk

• Anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema have been reported 1
• Reactions can occur days after administration
• Discontinue immediately if hypersensitivity occurs
• Quilipta is contraindicated in patients with prior hypersensitivity to atogepant 1

Administration Details

• Take with or without food 1
• Adherence is crucial—improvement occurs gradually over weeks 2
• Consider a 2-3 month trial period before switching agents 2

Common Pitfalls to Avoid

1. Don't use chronic migraine doses in severe renal impairment—this is explicitly contraindicated 1

2. Don't overlook drug interactions—CYP3A4 and OATP inhibitors/inducers require mandatory dose adjustments 1

3. Don't expect immediate results—counsel patients that preventive effects manifest gradually over the first few weeks 2

4. Don't forget pregnancy/lactation counseling—discuss adverse effects in patients of childbearing potential 2

5. Don't ignore cost—at approximately $5,000+ annually, ensure patients understand financial implications and explore less costly alternatives first per ACP recommendations 3, 2

Note on Lasmiditan Confusion

Important clarification: The question asks about "Quilipta dosing" but mentions "lasmiditan" in the expanded context. These are different medications:

• Quilipta (atogepant) = CGRP antagonist for migraine prevention
• Lasmiditan = 5-HT1F agonist (ditan) for acute migraine treatment, not prevention 3, 4

Lasmiditan is dosed 50-200 mg as needed for acute attacks 5, 6, while Quilipta is taken daily for prevention. The evidence provided about lasmiditan dosing [7-8] does not apply to Quilipta.